BOSTON, Sept. 23 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced that its Chief Executive Officer, Thomas J. Bigger, will present an overview of the company's strategy and research programs at the UBS Global Life Sciences Conference in New York next week. Details of the presentation follow: Date: Wednesday, September 29, 2004 Time: 4:00 p.m. (EDT) Location: The Grand Hyatt New York, Ballroom E Speaker: Thomas J. Bigger, Chief Executive Officer Audio Webcast: Available for 30 days on the Investor Relations page at http://www.paratekpharm.com Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and Multiple Adaptational Response ("MAR") Programs, as well as the company's most recent efforts to exploit its compounds and their unique mechanisms of action in selected anti-inflammatory and neurodegenerative conditions including multiple sclerosis. A copy of the Paratek presentation will be available upon request. About Paratek Pharmaceuticals Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek's lead programs are advancing novel compounds that can circumvent or block bacterial resistance, as well as drugs that can prevent infection by many gram-negative bacteria by interfering with Multiple Adaptational Response (MAR) mechanisms in bacteria. Out of these efforts, Paratek has discovered a new class of antibiotics, the aminomethylcyclines that target the need for new and potent antibacterials to overcome the problem of rapidly growing bacterial resistance. The Company's lead antibiotic clinical candidate, BAY 73-7388, the first product from this class, is being developed in a collaborative partnership with Bayer HealthCare AG. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.